At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 126 enrolled
Drug / intervention
pregabalindrug
Likely dose
pregabalin 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A LONG-TERM STUDY TO EVALUATE SAFETY AND EFFICACY STUDY OF PREGABALIN IN THE TREATMENT OF POSTHERPETIC NEURALGIA.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Jan 19, 2007·Updated Aug 27, 2021
In Brief
A Phase 3 clinical trial evaluating pregabalin for Neuralgia, Postherpetic. Completed, enrolled 126 participants across 33 sites.
Detailed Summary
To evaluate the safety of the long-term use of pregabalin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuralgia, Postherpetic
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
First PostedJan 2007
Primary CompletionAug 2008
TodayJul 2026
First PostedJan 19, 2007
Enrollment StartJan 12, 2007
Primary CompletionAug 19, 2008
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 19.5 years ago
Interventions
pregabalindrug
Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks